Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Wednesday 08 October, 2008

Lipoxen PLC

Change of Adviser Name

RNS Number : 3402F
Lipoxen PLC
08 October 2008
 



Lipoxen PLC 

('Lipoxen' or 'the Company') 

  

Change of Broker and Nominated Adviser Name 

 

Following its change of name from Landsbanki Securities (UK) Limited to Teathers Limited on 7 October 2008, the name of the Company's broker and nominated adviser is now Teathers Limited of: 

  

Beaufort House 

15 St Botolph Street 

London EC3A 7QR.


Enquiries 


Lipoxen PLC


M. Scott Maguire, Chief Executive Officer

+44 (0)20 7691 3583 



Teathers Limited (nominated adviser)


Shaun Dobson / Claes Spång 

+44 (0)20 7426 9000



Citigate Dewe Rogerson

+44 (0)20 7638 9571

David Dible / Heather Keohane



Notes to Editors

Lipoxen PLC (AIM:LPX) is a biopharmaceutical company specializing in the development of high value differentiated biologicals, vaccines and oncology drugs. Products currently under development include improved formulations of important biologicals such as erythropoietin (EPO), G-CSF, insulin and Interferon-alpha. Lipoxen has two products in clinical development SuliXen, a long acting insulin and long-acting EPO. These novel products, which are based on Lipoxen's proprietary PolyXen® technology, each address markets in excess of US$1 billion. 


Lipoxen's technology is designed to improve the stability, biological half-life and immunologic characteristics of therapeutic proteins naturally. Lipoxen has two further naturally-derived proprietary delivery technologies, ImuXen® and a related liposomal technology for the formulation of cytotoxic oncology drugs, which are being developed to enhance the efficacy and safety of various vaccines such as a multivalent Hepatitis B-E and pneumococcal vaccines, as well as a number of anti-cancer agents like paclitaxel. The Company's proprietary delivery technologies are attracting significant interest and Lipoxen is currently co-developing products with the Serum Institute of India Limited (one of the world's leading vaccine companies, India's largest biotech company and a major shareholder in Lipoxen) and has license agreements in place with Baxter International and InterVet, a leading animal health company.


Lipoxen was admitted to trading on the AIM Market of the London Stock Exchange in January 2006.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPFSWSWASASELS